Tag:
renal cell carcinoma
Latest Headlines
Latest Headlines
Germany's immatics bags $30M for cancer vaccine trial
Though the cancer vaccine field has seen more setbacks than successes, some companies are forging ahead with ambitious plans to push their therapeutics toward regulatory approval.
Immatics' kidney cancer vaccine extends lives in trials
Renal cell carcinoma patients lived longer when they developed responses to peptides in IMA901, Immatics' multipeptide therapeutic vaccine for kidney cancer, according to a new study published in Nature Medicine.
FDA gives Argos green light for kidney cancer immunotherapy
The FDA approved Argos Therapeutics' a revised Special Protocol Assessment (SPA) for its Phase III clinical study of AGS-003 for the treatment of metastatic renal cell carcinoma, or kidney cancer.
Argos garners $35.2M in third round
TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug
Press Release: AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Press Release: AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
ALSO NOTED: Aldagen raises venture funds; Thrombin submitted to FDA;and much more...
> Aldagen has raised $17.3 million its third round of venture financing. The round was co-led by Harbert Venture Partners and Intersouth Partners. Release > ZymoGenetics has filed rhThrombin for FDA approval. The therapy controls bleeding during surgery. Report > Wyeth Pharmaceuticals has gained priority review status for its NDA …
ALSO NOTED: Depomed surges on new data; FDA OKs Biomira study; and much more...
> Shares of Depomed surged on the news that a Phase II trial has produced data that demonstrates significantly reduced pain scores for patients taking one of two doses of its Gabapentin GR painkiller. Report > Biomira and the FDA have agreed on a clinical trial design to test Stimuvax for advanced lung cancer. …
Bayer, Onyx announce disappointing Nexavar results
In a late-stage disappointment, Bayer and partner Onyx Pharmaceuticals have announced that their skin cancer drug Nexavar did not meet the primary endpoint of progression-free survival. Nexavar, which has received both Fast Track and Orphan Drug Status, was approved last year as a therapy for advanced renal-cell carcinoma. Previously, Bayer and Onyx also announced that a …
ALSO NOTED: Wyeth looking for Torisel approvals; Nanogen streamlines;and much more...
> Wyeth Pharmaceuticals has submitted Torisel for approval in the U.S. and Europe for the treatment of advanced renal cell carcinoma. Report > San Diego-based Nanogen is planning to reduce its work force by about 50 positions in an effort to streamline operations. The company, which makes research and diagnostic tools, has built …
ALSO NOTED: FDA fast tracks Nexavar; ImClone, Merck KGaA amend pact; and much more...
> U.S. Sen. Charles Grassley (R-IA) has alleged that an FDA official collaborated with Merck to discredit FDA safety expert Dr. David Graham after he publicized health risks linked to Vioxx. Report > Bayer Pharmaceuticals and Onyx reported that the FDA has provided fast-track status for Nexavar as a therapy for advanced melanoma. Nexavar was approved last year as a therapy for advanced renal-cell …
- 1
- 2
- next ›
- last »
